Literature DB >> 29594746

Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future.

Ryan Eliott1, Pratik Panchal2,3, Shrish Budree1,4, Alex Scheeler1, Geraldine Medina1, Monica Seng1, Wing Fei Wong1, Thomas Mitchell5, Zain Kassam5, Jessica R Allegretti6,7, Majdi Osman1,6.   

Abstract

PURPOSE OF REVIEW: Universal stool banks (USBs) have emerged as a potential model for scaling access to fecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI). In this review, we outline the historical barriers constraining access to FMT, the evidence on methods and outcomes of USBs, and potential future directions for expanding access. RECENT
FINDINGS: Key historical barriers to FMT access include regulatory uncertainty, operational complexity of sourcing screened donor material, and logistical challenges of delivering fresh treatment preparations. USBs have demonstrated that FMT can be delivered safely at scale by centralizing donor selection, material processing, and safety monitoring. More evidence is needed to optimize USB methods, including for donor screening, material processing, and novel delivery modalities. USBs have catalyzed broad access to FMT in North America and Europe. Future directions include developing evidence regarding oral preparations, harmonizing guidelines, disseminating best practice protocols, establishing long-term safety profiles, and expanding access to geographic areas of unmet need.

Entities:  

Keywords:  Clostridium difficile infection; Donor screening; Fecal microbiota transplant; Geospatial; Microbiome; Universal Stool Bank

Mesh:

Year:  2018        PMID: 29594746     DOI: 10.1007/s11894-018-0619-8

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  63 in total

1.  Disseminating innovations in health care.

Authors:  Donald M Berwick
Journal:  JAMA       Date:  2003-04-16       Impact factor: 56.272

2.  [First experiences with faecal bacteriotherapy in the treatment of relapsing pseudomembranous colitis due to Clostridium difficile].

Authors:  Pavel Polák; Michaela Freibergerová; Jana Juránková; Hana Kocourková; Lucie Mikešová; Radek Svačina; Petr Husa
Journal:  Klin Mikrobiol Infekc Lek       Date:  2011-12

3.  Gastroenterologist perceptions of faecal microbiota transplantation.

Authors:  Sudarshan Paramsothy; Alissa J Walsh; Thomas Borody; Douglas Samuel; Johan van den Bogaerde; Rupert Wl Leong; Susan Connor; Watson Ng; Hazel M Mitchell; Nadeem O Kaakoush; Michael A Kamm
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

4.  Ensuring the safe and effective FDA regulation of fecal microbiota transplantation.

Authors:  Rachel E Sachs; Carolyn A Edelstein
Journal:  J Law Biosci       Date:  2015-07-06

5.  Treatment approaches including fecal microbiota transplantation for recurrent Clostridium difficile infection (RCDI) among infectious disease physicians.

Authors:  Johan S Bakken; Philip M Polgreen; Susan E Beekmann; Francis X Riedo; Judy A Streit
Journal:  Anaerobe       Date:  2013-09-04       Impact factor: 3.331

Review 6.  Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review.

Authors:  Giovanni Cammarota; Gianluca Ianiro; Antonio Gasbarrini
Journal:  J Clin Gastroenterol       Date:  2014-09       Impact factor: 3.062

Review 7.  The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis.

Authors:  Taha Qazi; Thelina Amaratunga; Edward L Barnes; Monika Fischer; Zain Kassam; Jessica R Allegretti
Journal:  Gut Microbes       Date:  2017-09-12

8.  The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals.

Authors:  Manasi Agrawal; Olga C Aroniadis; Lawrence J Brandt; Colleen Kelly; Sarah Freeman; Christina Surawicz; Elizabeth Broussard; Neil Stollman; Andrea Giovanelli; Becky Smith; Eugene Yen; Apurva Trivedi; Levi Hubble; Dina Kao; Thomas Borody; Sarah Finlayson; Arnab Ray; Robert Smith
Journal:  J Clin Gastroenterol       Date:  2016 May-Jun       Impact factor: 3.062

9.  Physician attitudes toward the use of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection.

Authors:  Jonathan Samuel Zipursky; Tivon I Sidorsky; Carolyn A Freedman; Misha N Sidorsky; Kathryn B Kirkland
Journal:  Can J Gastroenterol Hepatol       Date:  2014-04-09

10.  Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis.

Authors:  Gauree G Konijeti; Jenny Sauk; Mark G Shrime; Meera Gupta; Ashwin N Ananthakrishnan
Journal:  Clin Infect Dis       Date:  2014-03-31       Impact factor: 9.079

View more
  12 in total

1.  Establishing a donor stool bank for faecal microbiota transplantation: methods and feasibility.

Authors:  Anne A Rode; Peter Bytzer; Ole Birger Pedersen; Jørgen Engberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-07-04       Impact factor: 3.267

Review 2.  Treatment of Severe and Fulminnant Clostridioides difficile Infection.

Authors:  Yao-Wen Cheng; Monika Fischer
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12

Review 3.  SARS-CoV-2-associated gastrointestinal and liver diseases: what is known and what is needed to explore.

Authors:  Dina Sweed; Eman Abdelsameea; Esraa A Khalifa; Heba Abdallah; Heba Moaz; Inas Moaz; Shimaa Abdelsattar; Nadine Abdel-Rahman; Asmaa Mosbeh; Hussein A Elmahdy; Eman Sweed
Journal:  Egypt Liver J       Date:  2021-07-31

Review 4.  Orchestrating the fecal microbiota transplantation: Current technological advancements and potential biomedical application.

Authors:  Manisha Nigam; Abhaya Shikhar Panwar; Rahul Kunwar Singh
Journal:  Front Med Technol       Date:  2022-09-22

5.  Fecal Transplants by Colonoscopy and Capsules Are Cost-Effective Strategies for Treating Recurrent Clostridioides difficile Infection.

Authors:  Yuying Luo; Aimee L Lucas; Ari M Grinspan
Journal:  Dig Dis Sci       Date:  2019-09-06       Impact factor: 3.199

Review 6.  Mechanistic Insights in the Success of Fecal Microbiota Transplants for the Treatment of Clostridium difficile Infections.

Authors:  Amoe Baktash; Elisabeth M Terveer; Romy D Zwittink; Bastian V H Hornung; Jeroen Corver; Ed J Kuijper; Wiep Klaas Smits
Journal:  Front Microbiol       Date:  2018-06-12       Impact factor: 5.640

7.  [Fecal microbiota transplantation for patients with refractory diarrhea after allogeneic hematopoietic stem cell transplantation].

Authors:  Q Wang; Y W Fu; Y Q Wang; H Ai; F F Yuan; X D Wei; Y P Song
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-10-14

8.  Framework for rational donor selection in fecal microbiota transplant clinical trials.

Authors:  Claire Duvallet; Caroline Zellmer; Pratik Panchal; Shrish Budree; Majdi Osman; Eric J Alm
Journal:  PLoS One       Date:  2019-10-10       Impact factor: 3.240

9.  Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic.

Authors:  Gianluca Ianiro; Benjamin H Mullish; Colleen R Kelly; Zain Kassam; Ed J Kuijper; Siew C Ng; Tariq H Iqbal; Jessica R Allegretti; Stefano Bibbò; Harry Sokol; Faming Zhang; Monika Fischer; Samuel Paul Costello; Josbert J Keller; Luca Masucci; Joffrey van Prehn; Gianluca Quaranta; Mohammed Nabil Quraishi; Jonathan Segal; Dina Kao; Reetta Satokari; Maurizio Sanguinetti; Herbert Tilg; Antonio Gasbarrini; Giovanni Cammarota
Journal:  Gut       Date:  2020-07-03       Impact factor: 23.059

10.  Stool Banking for Fecal Microbiota Transplantation: Methods and Operations at a Large Stool Bank.

Authors:  Justin Chen; Amanda Zaman; Bharat Ramakrishna; Scott W Olesen
Journal:  Front Cell Infect Microbiol       Date:  2021-04-15       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.